Wherever he is short from, he is definitely in a better spot than you. His predictions has never failedBetter get your oxygen mask on. This is not Reddit. Your brainless pumping doesn't work here. The worse is yet to come.
Looking at the PPS and market cap drop the past year alone looks like
They failed in many ways. We don't see good sales numbers this is
Going to get real ugly. Company looks to be on life support.
I admit you're right!!! -- Because I don't make predictions, I state facts. I provide data. I don't guess. I don't say whether the stock will go up or down. I let intelligent people make up their own minds.
Me thinks Jess is gonna be right about this week, New yearly lows coming, We're gonna have a Pizza Party, All invited.
...and last Monday, and the Monday before that, and the Monday before that...but who's counting? What's important is that you're duck enough to admit it.
Why would any company be interested in buying BGMD? All they have is one miserable test and we don't even know if the test will do well in the market. The second indication as of now is dead. As for Noubar pumping in money, very unlikely. Good to read Noubar's interview last year and his view on diagnostics.
Over $1 just based on guidance is not going to happen. How do you know HDL sales are expected to go back to normal? HDL is no more. It depends what Trues Health wants to do know. Until we see revenue, nothing is certain.
Noubar is not going to put a cent unless the Galectin-3 test is selling well. If it is not selling it would be absolutely stupid for Noubar to put in money into a company that is sinking. How would re-submitting second indication contribute towards the profitability of the company. Even if they want to re-submit they need money to do the research and where is that going to come from? Noubar? Absolutely not. They will dilute and that will kill the pps. Why would True Health buy the test in large quantities? Whether the test has value or not remains to be seen from the revenue generated. 2nd indication at this point is as good as dead and Dirk is right, this will hit 20s soon.
The good that BG withdrew its application for a second indication? The news that it fired its CPA firm? The news that the 2 independent board members quit? The news that Noubar sold stock? Yep, it just keeps getting better and better.
So what if the stock has been DOWN EVERY MONDAY this month? So what if the stock is off 35% for the month? You go blu! No, really, go.
Abbott is selling this test, and HDL sales are expected to go back to normal by Q1, so at least revenues will increase. BG should hit profitability in 2016. Only need about 4$ million revenue. That will lead to higher SP, after which they will fund and complete FDA required study. Any positive guidance in March will do to launch SP over 1$.
They will get more funding from Noubar and Flagship and then contract out the studies like they've done the last few times. They're not going to let this company sink on a technicality, which is all this FDA delay is. The test is still good, has lots of value.
That is correct. Name one single thing that management has done over the last 2 years
that has strengthened or added value to the company. Can't think of anything?
That's because there isn't anything that they have contributed The automated
version was submitted by Abbott not BGMD. Like I said before if you drove the entire
management of BGMD off a cliff in a bus, the company wouldn't be any worse off.